These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23639982)

  • 1. Editorial to the themed issue on translational modeling in neuroscience.
    Bonate PL
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):255. PubMed ID: 23639982
    [No Abstract]   [Full Text] [Related]  

  • 2. Financial anatomy of neuroscience research.
    Dorsey ER; Vitticore P; De Roulet J; Thompson JP; Carrasco M; Johnston SC; Holloway RG; Moses H
    Ann Neurol; 2006 Dec; 60(6):652-9. PubMed ID: 17192926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drug approvals in 2002.
    Wynn RL
    Gen Dent; 2003; 51(3):212-6. PubMed ID: 15055702
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges and opportunities in neuroscience research.
    Coleman PJ; Barrow JC
    ChemMedChem; 2012 Mar; 7(3):339-41. PubMed ID: 22383223
    [No Abstract]   [Full Text] [Related]  

  • 5. Making translation work.
    Williams RS; Desmond-Hellmann S
    Science; 2011 Jun; 332(6036):1359. PubMed ID: 21680815
    [No Abstract]   [Full Text] [Related]  

  • 6. New drugs and drug products approved in 1997.
    Gage TW
    Tex Dent J; 1998 Sep; 115(9):51-60. PubMed ID: 9807157
    [No Abstract]   [Full Text] [Related]  

  • 7. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 9. A voyage of discovery.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 11. New drugs and product approvals from 2001.
    Taylor SE
    Tex Dent J; 2002 Dec; 119(12):1186-98. PubMed ID: 12592740
    [No Abstract]   [Full Text] [Related]  

  • 12. Near-record number of approvals signals drug development shift.
    Jiang K
    Nat Med; 2013 Feb; 19(2):114. PubMed ID: 23389589
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug pipeline: Q312.
    DeFrancesco L
    Nat Biotechnol; 2012 Dec; 30(12):1164. PubMed ID: 23222776
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of novel combination therapies.
    Woodcock J; Griffin JP; Behrman RE
    N Engl J Med; 2011 Mar; 364(11):985-7. PubMed ID: 21323535
    [No Abstract]   [Full Text] [Related]  

  • 15. Breakthrough drug category demands more communication.
    Carroll J
    Manag Care; 2013 Aug; 22(8):17-8. PubMed ID: 24024248
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 18. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omacetaxine: the FDA decision.
    Berman E
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):57-8. PubMed ID: 21326148
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.